Addition of TGF-β1 to existing clinical risk scores does not improve prediction for arrhythmia recurrences after catheter ablation of atrial fibrillation

Int J Cardiol. 2016 Oct 15:221:52-4. doi: 10.1016/j.ijcard.2016.06.290. Epub 2016 Jul 2.

Authors

Jelena Kornej¹, Laura Ueberham², Josephin Schmidl², Daniela Husser², Volker Adams³, Gerhard Hindricks², Andreas Bollmann²

Affiliations

¹ University of Leipzig, Heart Center, Department of Electrophysiology, Leipzig, Germany. Electronic address: [email protected].
² University of Leipzig, Heart Center, Department of Electrophysiology, Leipzig, Germany.
³ University of Leipzig, Heart Center, Department of Cardiology, Leipzig, Germany.

PMID: 27400297
DOI: 10.1016/j.ijcard.2016.06.290

No abstract available

Keywords: Atrial fibrillation; Catheter ablation; Fibrosis; Recurrences; Scores; TGF-β1.

Publication types

Letter

MeSH terms

Aged
Atrial Fibrillation* / blood
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / surgery
Catheter Ablation / adverse effects*
Catheter Ablation / methods
Female
Germany
Humans
Male
Middle Aged
Predictive Value of Tests
Prognosis
Recurrence
Research Design
Risk Assessment / methods*
Transforming Growth Factor beta1* / analysis
Transforming Growth Factor beta1* / blood

Substances

Transforming Growth Factor beta1